In our clinical intervention study applying an acute campylobacteriosis in vivo model, therapeutic butyrate treatment via the oral route resulted in reduced intestinal inflammatory sequelae, whereas gastrointestinal C. jejuni loads were not affected in infected microbiota-depleted IL-10−/− mice. Here, IL10 is linked to campylobacteriosis.